iwCLL 2019 | VENICE I: MRD response with venetoclax in R/R CLL

Arnon Kater

Arnon Kater, MD, PhD, University of Amsterdam, Amsterdam, The Netherlands, gives an update on the VENICE I Phase III study (NCT02756611) looking at measurable residual disease (MRD) response with venetoclax monotherapy in R/R chronic lymphocytic leukemia (CLL). This interview took place at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.

Share this video  
Similar topics